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Abstract
Retrovirology announces new editorial board members and reprises progress over the first two
years of publishing.
A word of thanks
As of this writing, Retrovirology has completed a little more
than 24 months of continuous publishing. The journal
has published 156 articles or roughly 6 articles per month,
all in Open Access format. Since retrovirus research is a
subsector of all virus research and Retrovirology considers
only basic science papers, this rate of monthly publication
seems reasonable at this juncture in journal development.
I am also pleased with the quality of the papers that Retro-
virology  has published. To a large extent credit for this
achievement must go to our Editorial Board members.
Hence, I take this opportunity to thank departing mem-
bers (Eric Arts, Steve Jacobson, Gerold Feuer, Kiyoshi
Takatsuki, Romas Geleziunas, Mika Salminen, W.A. Pax-
ton, Michel Tremblay, Naoki Yamamoto, Yoko Aida,
Masataka Nakamura, Klaus Uberla, Walter Guenzberg,
Myra McClure, Vanessa Hirsch, Vineet KewalRamani,
Wendy Maury, Pierre Corbeau, Guido Vanham and Lee
Ratner) who have served the journal ably over the last two
years. In turn, I welcome new members who have joined
Retrovirology  (Michael Burkrinsky, Kathy Boris-Lawrie,
David Derse, Juan Lama, Renaud Mahieux, Leonid Marg-
olis, Rogier Sanders, James K. Hildreth, Toshiki Watanabe,
Naoki Mori, Tatsuo Shioda, Ariberto Fassati, Tahir A.
Rizvi, Janice Clement, Chris Aiken, Neil Almond, Stephen
P. Goff, William Hall, Warner Greene, and Richard Zhao).
The full list of current Retrovirology Editors and Editorial
Board members can be viewed at http://www.retrovirol
ogy.com/edboard/.
The reasons for Open Access
Undeniably, retrovirus researchers are well-served by sev-
eral established subscription-based journals. However, on
the current scientific landscape, there is a choice between
two different ways of publishing research: the traditional
journal (where subscribers and sometimes authors pay)
and the Open Access model (where authors pay). The
Open Access model embraces a novel concept that
authors (or the funders of their research) pay for the sub-
mission and publication of papers. Once published, Open
Access articles are free in full text to all interested readers.
This means that your scientific colleague in Albania, the
aspiring graduate student in Kenya, the young doctor in
Chile, and the next James Watson or Alexander Fleming
from Vietnam can all have unfettered, fee-free, full access
to your Open Access article. Why would you want it any
other way?
I have a personal reason for supporting Open Access. I am
the 1 in 10 Americans born not in the United States but
overseas in a developing country. Thirty-five years ago, my
father was repeatedly rebuffed in his attempts to secure a
visa to enter the United States to study at a graduate
school. Had he not persevered, I might today be a frus-
trated scientist in a developing country unable to pay the
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subscription fees needed to read papers published in
Nature,  Cell  or  Virology. As science and societies move
increasingly toward globalization, I am convinced that we
all have a responsibility to work towards a knowledge
access model that transcends professional classifications,
national boundaries, and accidents of birth. As an Ameri-
can, I am confronted by the stark realization that in the
just passed year, 2005, 47% of the US national debt was
held by foreigners (a large portion by developing
nations), and that the American economy stays afloat
from an annual inflow of $216 billion from emerging
markets (Barron's, March 26, 2006). Hence, should it not
be viewed as simple fair reciprocity that American scien-
tists support Open Access as a small gesture of give-back
to the rest of the world?
Retrovirology's progress
Having stated the above, I don't believe that it is just altru-
ism which should guide authors to support Open Access.
A recently published study in PLOS Biology [1] showed
the tangible benefit of Open Access publishing. That study
clearly documented Open Access papers to be cited more
quickly and more frequently than non-Open Access
papers published in the same journal. Hence, it is perhaps
not surprising that some long standing traditionally sub-
scription-based journals such as Nucleic Acids Research and
Journal of Clinical Investigation have adopted the com-
pletely Open Access model as their new way of publish-
ing.
Retrovirology's  experience is consistent with the recent
report [1]. First, Retrovirology's  Open Access format
unquestionably attracts an impressively large readership.
For instance, the Journal of Molecular Biology, a leading sub-
scription journal, advertises as having been downloaded
"nearly 750,000" times in a single year (2002). Retrovirol-
ogy is a much smaller journal with perhaps 20 times fewer
published articles each year; and yet, Retrovirology  is
accessed an average of 1,700 times a day or over 600,000
times a year. I attribute this popularity to our Open
Access(ibility). Second, we see a good correlation between
the number of times that an article is read and the fre-
quency that it is cited in the literature. This has been veri-
fied by access statistics from several of Retrovirology's
already frequently cited papers (Fig. 1) [2-7]. Finally, my
impression is that Open Access has helped Retrovirology
achieve rapid name recognition and a respectable prelim-
inary Impact Factor number of nearly 3 (i.e. 2.98) just
after our very first year of publishing. Retrovirology's cur-
rent impact factor compares very favorably with those of
Virology and Journal of General Virology (Fig. 2).
An impact factor of 3 at age 2 is a good start for Retrovirol-
ogy. Nonetheless, I remain eager to receive your input as to
how Retrovirology can further improve and do better.
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Examples of Retrovirology articles that have been cited frequently within the first two years Figure 1
Examples of Retrovirology articles that have been cited frequently within the first two years. Data are from ISI's Web of Science.
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